ライフサイエンスコーパス: enrollment

1 .001, adjusting for disease duration, age of enrollment).

2 ia for severe asthma (P < .001 compared with enrollment).

3 TS1 from 57 families (age 23 +/- 17 years at enrollment).

4 onary angiography (within or after 24 h from enrollment).

5 m-/coma-free days by 1 week and 30 days post enrollment.

6 and 91% of relapses occurred by 2 years from enrollment.

7 were not taking dopaminergic medications at enrollment.

8 -0.78) patients were alive at 3 months after enrollment.

9 ose aged 9-14 years and on ART >=6 months at enrollment.

10 was the most frequent severity criterion for enrollment.

11 LWH not on ART and not virally suppressed at enrollment.

12 man immunodeficiency virus status at time of enrollment.

13 ter tomography angiography were eligible for enrollment.

14 all households within clusters were offered enrollment.

15 recurrent melioidosis within one year after enrollment.

16 sion or stratify patients for clinical trial enrollment.

17 dicating more severe pain) at 6 months after enrollment.

18 n SOFA score during the first 72 hours after enrollment.

19 specimens collected up to 28 days following enrollment.

20 A total of 8166 patients were screened for enrollment.

21 ls are plagued with escalating costs and low enrollment.

22 red in plasma collected 5 months after study enrollment.

23 al (CTLD7-CTLD8) region of PLA(2)R1 at study enrollment.

24 score remained lower than that of men after enrollment.

25 who had enhanced sensitivity to heat pain at enrollment.

26 s, laboratory, and respiratory variables) at enrollment.

27 nzania in 616 children aged 6 to 10 years at enrollment.

28 er diabetes or a normal glucose tolerance at enrollment.

29 e patients (67.6%) had grade III/IV aGVHD at enrollment.

30 dergo surgery at a median of 11 months after enrollment.

31 most individuals with early ILA detected at enrollment.

32 days (94% versus 82%; RD 12% [7%-17%]) after enrollment.

33 costeroids for at least 10 days before study enrollment.

34 ollected from 44 participants 6 months after enrollment.

35 ave excluded hypersensitized recipients from enrollment.

36 h NYHA functional class II symptoms at trial enrollment.

37 ts (50%) initiated INH preventive therapy at enrollment.

38 y enrolled in the ancillary study PREPARE at enrollment.

39 year, sex, ethnicity, and length of Medicare enrollment.

40 scretion of the primary care provider before enrollment.

41 residence at age 6 years, and year of study enrollment.

42 gn, CMR was performed in all the patients at enrollment.

43 ar before, during, and 1 year after SAFE-PCI enrollment.

44 n consent and assent will be obtained before enrollment.

45 for carotid endarterectomy are eligible for enrollment.

46 rial-eligible registry patients during trial enrollment.

47 in HIV care, starting 9 months after clinic enrollment.

48 th European ancestry and without dementia at enrollment.

49 ficiary's first 3 years of observed Medicare enrollment.

50 adjusting for duration of disease and age of enrollment.

51 8%, 58%, and 43% at 1, 5, and 10 years after enrollment.

52 mong persons who were SARS-CoV-2 negative at enrollment.

53 benefit allocation, and (c) eligibility and enrollment.

54 months, the study was terminated due to slow enrollment.

55 the patient's characteristics at the time of enrollment.

56 rquartile range 28-41]) were ART-eligible at enrollment.

57 neral ward) RSV disease at 5 to 9 days after enrollment.

58 ists nor antagonists within the month before enrollment.

59 Of 61 patients receiving apheresis at enrollment, 16 discontinued apheresis.

60 rge, US-based cohorts: Nurses' Health Study (enrollment 1976; follow-up 1982-2016; n = 81 869), Nurse

61 -2016; n = 81 869), Nurses' Health Study II (enrollment 1989; follow-up 2013-2017; n = 61 261), Siste

62 men's Health Initiative Observational Study (enrollment 1993-1998; follow-up 1993-2017; n = 73 267).

63 pplicators, 308 cases were diagnosed between enrollment (1993-1997) and the end of follow-up (2014-20

64 ased birth cohort in Rotterdam, Netherlands (enrollment 2002-2006).

65 low-up 2013-2017; n = 61 261), Sister Study (enrollment 2003-2009; follow-up 2003-2017; n = 40 647),

66 vided one spot urine and one blood sample at enrollment (2005-2015).

67 n children who had a liver transplant study (enrollment 2010-2013).

68 At enrollment (2017-2018), 1,493 participants with 6 or few

69 isease [MELD], 19.9 +/- 9.9), 36% had AKI at enrollment, 27% had previous AKI, and 61% developed new

70 At enrollment, 303 (34%) patients presented with de novo HF

71 At enrollment, 31% of the children had definite NASH, 34% h

72 versus 5.0 years), median CD4 count at study enrollment (506 versus 533 cells/mm3), and baseline rete

73 of the Penn Medicine Biobank (median age at enrollment 63 years, interquartile range 55-72; 38% fema

74 re common among those with early/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rar

75 By 8 months after study enrollment, 74% (220/296) of intervention and 59% (175/2

76 ve detectable SARS-CoV-2 in NTS collected at enrollment (8/13 [62%] vs 17/17 [100%]; P = .02).

77 accination event occurred within 15 years of enrollment, 83.3, 93.3, and 74.2% were positive by the B

78 istration rates had an immediate increase in enrollments after the intervention leading to higher reg

79 rapid ART initiation (within 30 days of care enrollment) after adoption of Treat All policies in 2 gr

80 ormula (2.1 g protein/100 kcal; n = 88) from enrollment (age <= 45 d) to 6 mo of age.

81 ll) improved rapid ART initiation after care enrollment among 10-14-year-olds in 7 sub-Saharan Africa

82 from 1 year before and 1 year after SAFE-PCI enrollment and 15 904 trial-eligible registry patients d

83 association between hyperglycemia and TB at enrollment and 3 months after TB treatment in the contex

84 = 11) or chronic EBV DNAemia (CD; n = 19) at enrollment and 4-8 weeks later.

85 atients with blood culture positive cases at enrollment and 6 weeks later to estimate the direct medi

86 incurred since illness onset by phone after enrollment and 6 weeks later.

87 ir caregivers from illness onset until after enrollment and 6 weeks later.

88 (SOFA) score (range, 0-24; 0 = best) between enrollment and 72 hours.

89 95% confidence interval [CI], 9.1%-15.4%) at enrollment and 9.3% (95% CI, 6.4%-13%) at follow-up; IGR

90 HIV/HCV serology was tested at enrollment and at 32- and 64-week follow-up visits.

91 Fecal samples were collected at enrollment and at 7, 28, and 56 days after beginning tre

92 dized detailed questionnaire administered at enrollment and at repeated phone interviews in the perio

93 After study enrollment and baseline measures, participants consumed

94 Enrollment and CNI withdrawal were stopped after 43/60 p

95 nds in family income inequalities in college enrollment and completion ("collegiate inequalities") us

96 During this period, inequality in college enrollment and completion was significantly higher for m

97 with 2 free finger-prick-based HIVST kits at enrollment and could receive 2 to 4 kits delivered throu

98 ase chain reaction and CDSS were measured at enrollment and daily in inpatients.

99 a, travel and contact history, and saliva at enrollment and daily nasopharyngeal/throat swabs (NTSs)

100 Enrollment and data collection began in May 2018 and wil

101 HAPIN enrollment and data collection began in May 2018 and wil

102 V antibody and/or HCV RNA within 6 months of enrollment and either acute clinical hepatitis within th

103 d as new positive HCV RNA within 6 months of enrollment and evidence of prior spontaneous or treatmen

104 xcluding the first 6 months to 2 years after enrollment and excluding individuals with comorbid heart

105 2%-51.8%) and 21.5% (95% CI, 16.9%-26.3%) at enrollment and follow-up.

106 major health events in the 5 years prior to enrollment and had sufficient mobility and good cognitiv

107 count of 537 cells/mul (IQR: 483 to 741) at enrollment and HIV plasma viral loads of <40 copies/ml.

108 titers were detected in 6 of 12 patients on enrollment and in 11 of 12 at >=2 time points.

109 39%, 32%, and 37% at 1, 5, and 10 years post-enrollment and PAFs were 20%, 14%, and 15%.

110 Contactless methods of recruitment, enrollment and sample collection were utilized throughou

111 tomography (Heidelberg Engineering, Inc) at enrollment and subsequent follow-ups.

112 The study measured creatinine at enrollment and test of cure, serum gentamicin concentrat

113 e collected nasopharyngeal or nasal swabs at enrollment and tested for SARS-CoV-2 using a real-time P

114 subsequently recommended the termination of enrollment and the reporting of the results.

115 as Heart Study) underwent CAC measurement at enrollment and were followed for incident ASCVD events.

116 received a liver transplant >=1 year before enrollment and were subsequently treated with tacrolimus

117 s treated with azithromycin-based therapy at enrollment and who completed the follow-up survey, persi

118 nical Frailty Scale at baseline (i.e., study enrollment) and at 3 and 12 months postdischarge.

119 rial fibrillation (diagnosed <=1 year before enrollment) and cardiovascular conditions to receive eit

120 Also, 10.1% were LTFU within 7 days of enrollment, and 15.2% were LTFU at 1 year (6.7% prior to

121 had a positive WHO symptom screen for TB on enrollment, and 45% were diagnosed with microbiologicall

122 ge, sex, race, socioeconomic status, date of enrollment, and comorbidities.

123 guide clinical decision-making, inform trial enrollment, and facilitate comprehensive patient recover

124 according to center, sex, age, and period of enrollment, and including as potential confounders a fam

125 ndrome was present in 89 patients (18.7%) at enrollment, and new or progressive multiple organ dysfun

126 arm nonlinkers, 6 had not initiated ART upon enrollment, and no acquired DRMs were detected.

127 verity of fibrosis, calendar year of patient enrollment, and other potential confounders, vitamin E t

128 r both mGCIPL and pRNFL structural change at enrollment, and then evaluated for longitudinal OCT or H

129 ve tract infections (RTIs) within 1 month of enrollment, and virologically suppressed using ART or ab

130 ortium (ROC) Cardiac Epidemiologic Registry (enrollment, April 2011-June 2015 from 10 North American

131 nt ART history review and HIVDR testing upon enrollment at 12 clinics in Uganda, Kenya, Tanzania, and

132 diagnosis and at least 2 years of continuous enrollment before and after diagnosis were identified.

133 Enrollment began in December 2007 and follow-up was comp

134 Enrollment began in July 2013 and ended in May 2014; the

135 iversity hospital trauma centers in Finland, enrollment between November 2012 and January 2018 with a

136 At enrollment, both the H3N2 negative and positive patients

137 Ten patients not diagnosed with cirrhosis at enrollment but median APRI >= 2.0 developed HCC.

138 ids and/or intravenous immunoglobulin) after enrollment but prior to a primary outcome, to evaluate H

139 zard of death by 63% in the first year after enrollment, but 93% of these started ART; thus universal

140 re more likely to have ophthalmic disease at enrollment, but there was no difference in incidence onc

141 re systematically higher for (and thus deter enrollment by) landholders who would have conserved anyw

142 ale, median age 35 years [IQR 29-41], median enrollment CD4 count 280 cells/mul [IQR 146-431]) were i

143 0% were female (N = 11,241), they had median enrollment CD4 count of 220 cells/mul, and 38% had WHO s

144 ria, such as clinical status, pregnancy, and enrollment CD4 count, which precluded the assessment of

145 At enrollment, CMV DNAemia >=1000 copies/mL (defined as "cl

146 ldren underwent neurocognitive evaluation at enrollment (community children) or a week following hosp

147 Alternatively, enrollment costs can dampen per-enrollee benefits if the

148 Enrollment costs can increase a program's benefits per e

149 consider investing in QHPs because increased enrollment could improve VS rates.

150 dministration-approved instructions for use (enrollment criteria plus NT-proBNP <1,600 pg/ml), consis

151 l or EDOF IOLs; however, corneal topographic enrollment criteria were not specified.

152 Among 691,961 patients meeting the enrollment criteria, 266,374 (38.5%) received prolonged

153 ized patients with HFrEF using the following enrollment criteria: current New York Heart Association

154 We analyzed Medicare claims and enrollment data for a group of fee-for-service beneficia

155 e conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle

156 a highly pragmatic design allowed efficient enrollment, data acquisition, and monitoring, interventi

157 =2 asthma exacerbations in the year prior to enrollment, despite receiving high-dose inhaled corticos

158 We conducted an analysis of screening and enrollment during 2003-2013 to 31 clinical trials at 99

159 e hassle of signing up or financial costs of enrollment (e.g., purchasing seedlings) can affect who p

160 ith familial interstitial pneumonia.Methods: Enrollment evaluation included a health history and expo

161 tion, because cholera outbreaks enable large enrollment, field methods are well established, and the

162 (index date), and they had to maintain their enrollment for at least 18 months thereafter.

163 tion period extended from 3 months post-BPCI enrollment for each SNF through December 2017.

164 safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the L

165 alysis of the National Lung Screening Trial (enrollment from 2002-2004), a randomized controlled tria

166 PARTICIPANTS: Cluster randomized trial with enrollment from July 19, 2016, through August 10, 2017,

167 e, there is little reason to expect that the enrollment gap will decrease, given the stagnating readi

168 The enrollment goal of 125 patients was met.

169 Our enrollment goal was 30 LGI1/CASPR2-IgG-seropositive adul

170 Eight women with rectal CT at enrollment had at least 1 rectal CT-positive NAAT after

171 tomatic or had mild/moderate claudication at enrollment had no change in symptom classification over

172 re include race/ethnicity, poverty, Medicaid enrollment, housing built before 1950, and age.

173 igher body mass index, high-income region of enrollment, hypertension, and tenofovir disoproxil fumar

174 QHP enrollment in 2015 was associated with QHP coverage in 2

175 e of both stroke and cognitive impairment at enrollment in a cognitive substudy (1995-2001).

176 The TB/DM association was significant at enrollment in both new and preexisting DM, but only pers

177 d girls' education, which suppresses college enrollment in both sexes, but for different reasons.

178 17 adults who were aged 30-89 years at their enrollment in Cancer Prevention Study II in 1982.

179 Also, it is a prerequisite for enrollment in clinical trials, and to date, no other tre

180 urvival among persons with and without TB at enrollment in HIV care, starting 9 months after clinic e

181 osa, had 12 months of continuous health care enrollment in Kaiser Permanente Northwest, and had a per

182 OVID-19 pandemic, it is appropriate to defer enrollment in lung cancer screening and modify the evalu

183 All of Us opened for enrollment in May 2018 and currently enrolls participant

184 and adults had to have 24 months continuous enrollment in Medicaid prior to the first antibiotic ear

185 significant TB/DM and TB/IGR association at enrollment in newly diagnosed DM, but persistent hypergl

186 re recent trial manuscript publication year, enrollment in North America (versus Western Europe), fem

187 Subjects who completed PEPITES were offered enrollment in PEOPLE.

188 ic and facilitate research studies including enrollment in prevention and treatment trials.

189 d girls attending university can predict the enrollment in tertiary education 5 y later.

190 s used to identify enrollees with continuous enrollment in the database for 365 days or more.

191 >=75 years, those with earlier versus later enrollment in the Swedish heart failure registry, and pa

192 he median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range,

193 Referral was associated with increased enrollment in WM, weight loss, and decreased ALT.

194 roximately 13% over 2 years owing the rising enrollments in Medicare offset by the cost of care per a

195 fices run by an OPO was associated with more enrollments independent of the increasing trend of enrol

196 models for these sequential processes of RCT enrollment, information generation, and the resulting tr

197 enotypes were performed during screening for enrollment into a trial of third-line ART (AIDS Clinical

198 with acute respiratory distress syndrome for enrollment into randomized controlled trials has come at

199 ation in CRC screening within 18 weeks after enrollment into the study.

200 Enrollment is associated with VS across states/demograph

201 per discusses the less-appreciated fact that enrollment is often based on other factors too.

202 icipants with AD and 47 without AD (dates of enrollment, May 2007-January 2019); the Swedish BioFINDE

203 regard to SOFA score over the 72 hours after enrollment (mean SOFA score change from 9.1 to 4.4 [-4.7

204 d pVL across 6 and 24 months controlling for enrollment measures, ART group, age, and RTI using gener

205 issions during the 6 months before and after enrollment misleadingly suggested a 38-percentage-point

206 Older persons without dementia at study enrollment (n = 1,010) had annual cognitive testing for

207 se of trivalent GBS vaccine 4-6 years before enrollment (n = 53) or never GBS vaccinated (n = 27) rec

208 AKI (SHR, 1.26; 1.02-1.56), and AKI stage at enrollment (no AKI [SHR, 1] vs. stage 1 [SHR, 3.28; 1.30

209 ed using ART or above treatment threshold at enrollment (non-ART).

210 Enrollment occurred between November 2013 and July 2017;

211 Enrollment occurred from January 2011 to August 2015; 24

212 The first study enrollment occurred on November 18, 2015; the final stud

213 double-blind, randomized, multicenter trial (enrollment October 30, 2014, to June 14, 2017; study ter

214 TB/DM association was significant at enrollment (odds ratio [OR], 2.41 [95% CI, 1.3-4.3]) and

215 After enrollment of 17 patients (LGI1-IgG, 14; CASPR2-IgG, 3)

216 After the enrollment of 205 patients, the trial was prematurely st

217 nded early termination of the study prior to enrollment of 440 patients because of safety.

218 and expert optic nerve sheath diameter after enrollment of 50 subjects was poor at 0.16 (-0.08 to 0.4

219 This study characterizes annual changes in enrollment of Medicare and non-Medicare patients treated

220 The enrollment of patients in the hydroxychloroquine group w

221 tual negotiations, and lack of access to and enrollment of study subjects.

222 September 2013, which was 9 months prior to enrollment of the first BPCI cohort.

223 developed TB disease at least 15 days after enrollment of the index patient.

224 clinical trial design constraints hinder the enrollment of those populations at the greatest risk for

225 s significant, even allowing for the greater enrollment of women (permutation P=0.004, median differe

226 r of women authors is associated with higher enrollment of women in HF trials.

227 25 (19.4%) had an ILD event by 5 years after enrollment; of these, 12 met the study endpoint and anot

228 gain in visual acuity, whether instituted at enrollment or after 1 year of monthly treatment.

229 ained CPE-colonized at the time of household enrollment (OR 7.00, 95% CI 1.92-25.49), or if they had

230 reas TB/IGR association was only positive at enrollment (OR, 2.3 [95% CI, 1.6-3.3]).

231 ments independent of the increasing trend of enrollment (P < 0.001).

232 sites were associated with lung function at enrollment (P < 0.05).

233 al: 1.02, 1.26) in those aged 70-89 years at enrollment (P for trend = 0.005).

234 At enrollment, participants at 11 HIV clinics in Kenya, Uga

235 Upon enrollment, participants received daily oral tenofovir d

236 At enrollment, patients were assigned to 4 treatment groups

237 y of tumors, after controlling for age, sex, enrollment period, and paternal origin (adjusted HR, 3.2

238 by GBD region, with shifts during the trial enrollment period.

239 At enrollment, postchemotherapy participants (n = 74) were

240 ics and healthcare delivery factors with QHP enrollment prevalence and 1-year risk of VS.

241 who had received conventional therapy before enrollment (previously treated patients) and previously

242 Due to the size and enrollment procedures, collection of the metabolomes for

243 lled, double-blind, parallel-group, enriched enrollment randomized withdrawal trial conducted at the

244 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without co

245 Preintervention registry enrollment rates per month were 10%-50%.

246 Because of the 2:1 female-to-male enrollment ratio, women and men were compared with permu

247 with HoFH, including 14 <18 years of age at enrollment) received evolocumab for a median of 4.1 year

248 The end points assessed feasibility (enrollment, retention, and adherence), safety (dose leve

249 Enrollment started in February 2016, with a goal of 400

250 .23]) (P < .001 for interaction between dual enrollment status and time).

251 s, estimated glomerular filtration rate, and enrollment strata.

252 ss the effect on study outcomes of different enrollment strategies for a noninferiority trial of LTBI

253 Five enrollment strategies were assessed: 1) enroll based on

254 od and good viral suppression at the time of enrollment, the HIV+ group had poorer neuropsychological

255 Among patients with AD at enrollment, those with the highest baseline KP activity

256 rtphone accelerometer data continuously from enrollment through 6 months postoperatively.

257 : 1.18, 1.33) in persons aged 30-49 years at enrollment to 1.13 (95% confidence interval: 1.02, 1.26)

258 om median values of 481 (IQR: 387-798) uM at enrollment to 1046 (IQR: 616-1220) uM 5 d later (P < 0.0

259 ased from 69.5 per 100 person-years prior to enrollment to 98.4 per 100 person-years during follow-up

260 onducted a follow-up interview 6 weeks after enrollment to ascertain final outcomes.

261 tus/pre-diabetes mellitus), longer time from enrollment to death, more recent trial manuscript public

262 Respiratory swabs were collected at enrollment to identify and quantify bacterial species vi

263 Respiratory swabs were collected at enrollment to identify and quantify bacterial species vi

264 to 999 g at less than 72 hours after birth; enrollment took place between July 14, 2011, and Novembe

265 Enrollment took place between July 2017 and February 202

266 e primary outcome was daily weight gain from enrollment up until the age of 17 wk (at an equivalence

267 and survival were indexed at 6 months after enrollment using a landmark approach.

268 mor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with

269 bservational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same cen

270 Upon enrollment, validated data were collected on demographic

271 Mucosal samples were collected once at the enrollment visit (between 15 and 35 weeks of gestation)

272 as detected in 142/355 (40%) isolates at the enrollment visit.

273 (COPD) using blood samples from the COPDGene enrollment visit.

274 ange 27-76), and median time from alloHCT to enrollment was 21 months (range 5.6-108.5).

275 Median time from diagnosis to enrollment was 23 months (interquartile range, 4-122), w

276 The median age at enrollment was 3.2 months (interquartile range, 1.7-5.8

277 The median age at enrollment was 38 years, and 51% of participants were fe

278 Among 55,908 participants, the mean age at enrollment was 48.3 years, 26,324 (47.1%) were men, and

279 median time between prior therapy and trial enrollment was 9 months (range, 1-180 months).

280 A history of HPEEs reported at enrollment was associated with a higher likelihood of re

281 Data about registry enrollment was collected before and during the 4-year OP

282 Enrollment was conducted between May 23, 2016, and Decem

283 Study enrollment was discontinued by the Scientific Monitoring

284 Retrospective case enrollment was done at 1 hospital from July 2012 through

285 Enrollment was stopped because of slow recruitment after

286 Enrollment was stopped early due to concern for harm bas

287 However, enrollment was suboptimal, triggering premature study di

288 of 57,053 individuals 50-64 years of age at enrollment, we identified 21,241 individuals who fulfill

289 HPEEs that occurred after enrollment were also associated with OI development.

290 Outcomes at 3 weeks after enrollment were categorized as spontaneous survivor (SS)

291 ab (n=23) more than one month prior to their enrollment were recruited.

292 RSV infection and >=24 months of continuous enrollment were retrospectively identified from the Truv

293 ization claims and >=24 months of continuous enrollment were retrospectively identified in the Truven

294 hite cell count, and day of illness at study enrollment were significant predictors of poor platelet

295 pe and interval from first delivery to study enrollment) were selected using incidence sampling metho

296 lected retrospectively for 3 months prior to enrollment, were used to track the quantity (number of i

297 At the time of study enrollment when a formal LVAD evaluation was initiated,

298 protein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended J

299 ts (median of 2 cycles commencing 359 d from enrollment), with a PSA decline of at least 50% in 11 pa

300 intraocular lens (IOL) placement during IATS enrollment years 2004 through 2010.